vesemnogene lantuparvovec (AAV-hSMN1) / Lantu Biopharma - LARVOL DELTA

Real World Clinical Effectiveness & Safety of Vesemnogene Lantuparvovec for Spinal Muscular Atrophy (SMA) in Low-middle Income Countries (LMIC). (clinicaltrials.gov) - P3 | N=15 | Recruiting | Sponsor: Lantu Biopharma

New P3 trial • Real-world evidence • Genetic Disorders • Movement Disorders • Muscular Atrophy • Rare Diseases

An Open Label Study of Gene Therapy Product (Vesemnogene Lantuparvovec) in Spinal Muscular Atrophy (clinicaltrials.gov) - P1/2 | N=6 | Recruiting | Sponsor: Lantu Biopharma | Trial completion date: Jul 2027 ➔ Oct 2027 | Trial primary completion date: Jul 2027 ➔ Oct 2027

Gene therapy • Trial completion date • Trial primary completion date • Gene Therapies • Genetic Disorders • Movement Disorders • Muscular Atrophy • Rare Diseases

An Open Label Study of Gene Therapy Product (Vesemnogene Lantuparvovec) in Spinal Muscular Atrophy (clinicaltrials.gov) - P1/2 | N=6 | Recruiting | Sponsor: Lantu Biopharma | Not yet recruiting ➔ Recruiting | Trial completion date: Mar 2027 ➔ Jul 2027 | Initiation date: Mar 2024 ➔ Jul 2024 | Trial primary completion date: Mar 2027 ➔ Jul 2027

Enrollment open • Gene therapy • Trial completion date • Trial initiation date • Trial primary completion date • Gene Therapies • Genetic Disorders • Movement Disorders • Muscular Atrophy • Rare Diseases

An Open Label Study of Gene Therapy Product in Spinal Muscular Atrophy Patients (clinicaltrials.gov) - P1/2 | N=6 | Not yet recruiting | Sponsor: Lantu Biopharma

New P1/2 trial • Gene Therapies • Genetic Disorders • Movement Disorders • Muscular Atrophy • Rare Diseases